NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, vehicle-controlled, parallel group dose response study
evaluating the safety and effectiveness of 2 concentrations of NFX-179 Gel in subjects with
cutaneous neurofibromas. At Visit 1, the investigator will identify 10 Target cNFs that
fulfil the enrollment criteria. The Target cNFs must be located on the subject's face,
anterior trunk, or upper extremities. Two Target cNFs must be on the face and 8 must be on
the anterior trunk or upper extremities. The study medication will be applied topically QD to
the Target cNFs for 182days (26 weeks). During the duration of the study subjects will be
evaluated for safety and efficacy.